8
Apr 2026
New monoclonal antibody shows promise for preventing Lyme disease
A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.